{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:56:50Z","timestamp":1775797010433,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Anti-programmed death 1 (PD-1) monoclonal antibodies improve the survival of metastatic melanoma patients. Predictive or monitoring biomarkers for response to this therapy could improve the clinical management of these patients. To date, no established biomarkers are available for monitoring the response to immunotherapy. Tumor- specific mutations in circulating tumor DNA (ctDNA) such as<jats:italic toggle=\"yes\">BRAF<\/jats:italic>and<jats:italic toggle=\"yes\">NRAS<\/jats:italic>mutations for melanoma patients have been proposed for monitoring of immunotherapy response. We present seven illustrative cases for the use of ctDNA<jats:italic toggle=\"yes\">BRAF<\/jats:italic>and<jats:italic toggle=\"yes\">NRAS<\/jats:italic>mutations\u2019 monitoring in plasma. The cases described exemplify four distinct clinical benefit patterns: rapid and durable complete response (CR), early progression, followed by CR, CR followed by early progression after interrupting treatment and long-term disease stabilization. These representative cases suggest that comprehensive<jats:italic toggle=\"yes\">BRAF<\/jats:italic>\/<jats:italic toggle=\"yes\">NRAS<\/jats:italic>ctDNA monitoring during anti-PD1 therapy is informative and can be of added value for the monitoring of melanoma patients gaining clinical benefit on anti-PD1 treatment. An important advantage of our approach is that using the cartridge system on the Idylla platform for mutation analysis, the results become available the same day 2\u2009h after plasma collection. Therefore, in the future, the ctDNA level can be an element in the clinical management of the patients.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000415","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T19:18:16Z","timestamp":1512847096000},"page":"65-70","source":"Crossref","is-referenced-by-count":20,"title":["Illustrative cases for monitoring by quantitative analysis of BRAF\/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy"],"prefix":"10.1097","volume":"28","author":[{"given":"Teofila","family":"Seremet","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel"},{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Planken","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Schreuer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Delaunoy","sequence":"additional","affiliation":[{"name":"Department of Genetics, Laboratory of Medical Genetics, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakim","family":"El Housni","sequence":"additional","affiliation":[{"name":"Department of Genetics, Laboratory of Medical Genetics, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Lienard","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Del Marmol","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Heimann","sequence":"additional","affiliation":[{"name":"Department of Genetics, Laboratory of Medical Genetics, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2217\/imt.15.111","article-title":"Immunotherapy for advanced melanoma: future directions","volume":"8","author":"Valpione","year":"2016","journal-title":"Immunotherapy"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/jco.2015.33.15_suppl.3000","article-title":"Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001","volume":"33","author":"Wolchok","year":"2015","journal-title":"J Clin Oncol"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/CMR.0000000000000224","article-title":"Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma","volume":"26","author":"Schreuer","year":"2016","journal-title":"Melanoma Res"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","article-title":"Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors","volume":"14","author":"Schreuer","year":"2016","journal-title":"J Transl Med"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","article-title":"Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade","volume":"2","author":"Lipson","year":"2014","journal-title":"J Immunother Cancer"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.molonc.2015.09.005","article-title":"Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression","volume":"10","author":"Chang","year":"2016","journal-title":"Mol Oncol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/S0959-8049(16)31846-9","article-title":"3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III\/IV melanoma patients who are disease-free following the local treatment of macrometastases","volume":"51","author":"Jansen","year":"2015","journal-title":"Eur J Cancer"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00009","article-title":"Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma","volume":"1","author":"Wong","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","volume":"28","author":"Cabel","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201802000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T15:49:36Z","timestamp":1719676176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201802000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000415","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}